Immuneering Corporation Class A share price logo

Immuneering Corporation Class A

NASDAQ: IMRX

Small Cap

$5.05

+0.29

(+6.20%)

as on

Immuneering Corporation Class A Stock Performance

as on June 30, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $4.65
    $5.14
    downward going graph

    7.92%

    Downside

    1.78%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.90
    $10.08
    downward going graph

    42.57%

    Downside

    99.60%

    Upside

    downward going graph

Immuneering Corporation Class A share price movements today

Previous Close
$4.76
Open
$4.65
Volume
2.1M
Day's Low - High
$4.65 - $5.14
52 Week Low - High
$2.90 - $10.08

Immuneering Corporation Class A Historical Returns

1 Month Return
-17.5 %
3 Month Return
-4.03 %
1 Year Return
+ 34.84 %
3 Year Return
-50.31 %
5 Year Return
0 %

Immuneering Corporation Class A Stock Fundamentals & Key Indicators

Check Immuneering Corporation Class A market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$308.0M

EPS (TTM)

-1.1367

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-58.9M

Revenue (TTM)

455.0

Profit Margin

0.00%

Return On Equity TTM

-43.84%

Immuneering Corporation Class A vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immuneering Corporation Class A with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Immuneering Corporation Class A image
Immuneering Corporation Class A
BUY$308.0MNANA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$38.7B470.07%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$38.9B75.66%73.0312.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$124.7B149.69%29.1635.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$66.4B15.92%15.4629.65%0.58%

Stock Returns calculator for Immuneering Corporation Class A Stock including INR - Dollar returns

The Immuneering Corporation Class A stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Immuneering Corporation Class A investment value today

Current value as on today

₹1,57,816

Returns

₹57,816

(+57.82%)

Returns from Immuneering Corporation Class A Stock

₹43,059 (+43.06%)

Dollar Impact

₹14,757 (+14.76%)

Analyst Recommendation on Immuneering Corporation Class A Stock

Based on 14 analysts

BUY

71.43%

Buy

28.57%

Hold

0.00%

Sell

Based on 14 analysts, 71.43% of analysts recommend a 'BUY' rating for Immuneering Corporation Class A. Average target price of $17

Immuneering Corporation Class A Share Price Target

Get share price movements and forecasts by analysts on Immuneering Corporation Class A.

What analysts predicted

70.29%UPSIDE

Target Price

$17

Current Price

$5.05

Analyzed by

14 Analysts

Target

$17.00

Immuneering Corporation Class A target price $17, a slight upside of 70.29% compared to current price of $5.05. According to 14 analysts rating.

Indian Investors' Interest in Immuneering Corporation Class A Stock

Search interest for Immuneering Corporation Class A Stock has increased by 19% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:19% versus previous 30 day period

Immuneering Corporation Class A Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
-94
-
-
-
0
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-16
-15
-14
-15
-18
-15
-14
-15
-13
-15
EBITDA
-14
-15
-14
-15
-17
-15
-14
-15
-13
-15
Interest Expense
1,075
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-15
-14
-14
-14
-18
-15
-14
-14
-11
-13
Income Tax Expense
0
0
0
0
0
-
-
-
-
-
Net Income
-15
-14
-14
-14
-18
-15
-14
-14
-11
-13
Net Profit Margin
15.98%
0.00%
0.00%
0.00%
-2485.31%
0.00%
0.00%
0.00%
0.00%
0.00%

Immuneering Corporation Class A Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
2
2
0
0
-
-
Gross Profit
0
1
0
0
0
0
0
Operating Income
-6
-17
-33
-51
-58
-64
-59
EBITDA
-7
-17
-33
-51
-58
-63
-55
Interest Expense
0
0
0
1
-
-
-
Depreciation
0
0
0
0
0
0
0
Income Before Tax
-7
-17
-33
-50
-53
-61
-56
Income Tax Expense
0
0
0
-1
0
-
-
Net Income
-7
-17
-33
-50
-53
-61
-56
Net Profit Margin
-401.59%
-737.17%
-1612.33%
-15937.29%
-11752004.84%
0.00%
0.00%

Immuneering Corporation Class A Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-14
-14
-14
-18
-15
-14
-14
-11
-13
Operating Cash Flow
-15
-11
-13
-14
-14
-9
-11
-9
-18
Investing Cash Flow
21
4
-5
5
0
0
0
-88
-63
Financing Cash Flow
0
-
4
0
13
0
213
0
0
Change in Cash
6
-6
-14
-9
0
-9
201
-98
-81

Immuneering Corporation Class A Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-17
-33
-50
-53
-61
-56
Operating Cash Flow
-14
-30
-44
-48
-54
-45
Investing Cash Flow
0
-75
41
7
26
-88
Financing Cash Flow
37
144
0
28
5
226
Change in Cash
23
37
-2
-13
-23
92

Global Institutional Holdings in Immuneering Corporation Class A

Funds
Holdings
Connor Clark & Lunn Inv Mgmt Ltd
0.62%
The Goldman Sachs Group Inc
0.51%
HighTower Advisors, LLC
0.32%
DCF Advisers, LLC
0.33%
Vanguard Fiduciary Trust Co
0.5%
See all

Immuneering Corporation Class A News & Key Events

    Insights on Immuneering Corporation Class A

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 7 days, IMRX stock has moved up by 7.2%

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 2 quarters, -94.41M → 726.32K (in $), with an average increase of 13099.5% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Revolution Medicines, Inc. Common Stock has given 393.3% return, outperforming this stock by 358.5%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Revolution Medicines, Inc. Common Stock has given 594.4% return, outperforming this stock by 644.7%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, -11.58M → -13.46M (in $), with an average decrease of 16.2% per quarter

    About Immuneering Corporation Class A

    Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
    OrganisationImmuneering Corporation Class A
    Headquarters245 Main Street, Cambridge, MA, United States, 02142
    IndustryBiotechnology
    CEODr. Benjamin J. Zeskind M.B.A., Ph.D.
    E-voting on sharesClick here to vote

    Key Management of Immuneering Corporation Class A

    Name

    Title

    Ms. Paula George CPA

    Director of Accounting & Operations and Assistant Corporate Controller

    Dr. Peter King Ph.D.

    Head of Discovery & VP

    Dr. Benjamin J. Zeskind M.B.A., Ph.D.

    Co-Founder, President, CEO & Director

    Mr. Robert J. Carpenter M.B.A., M.S.

    Co-Founder & Chair Emeritus

    Ms. Courtney Dugan

    VP and Head of Investor Relations & Corporate Communications

    Ms. Leah R. Neufeld

    Chief People Officer

    Dr. Praveen Nair Ph.D.

    Head of Translational Pharmacology & VP

    Dr. Igor Matushansky M.D., Ph.D.

    Chief Medical Officer

    Dr. Brett M. Hall Ph.D.

    Chief Scientific Officer

    Mr. Michael D. Bookman J.D.

    Chief Legal Officer & Secretary

    FAQs

    What is Immuneering Corporation Class A share price today?

    Immuneering Corporation Class A share price today is $5.05 as on at the close of the market. Immuneering Corporation Class A share today touched a day high of $5.14 and a low of $4.65.

    What is the 52 week high and 52 week low for Immuneering Corporation Class A share?

    Immuneering Corporation Class A share touched a 52 week high of $10.08 on and a 52 week low of $2.9 on . Immuneering Corporation Class A stock price today i.e. is closed at $5.05,which is 49.90% down from its 52 week high and 74.14% up from its 52 week low.

    What is Immuneering Corporation Class A's market capitalisation today?

    Immuneering Corporation Class A market capitalisation is $0.00T as on .

    How to invest in Immuneering Corporation Class A Stock (IMRX) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Immuneering Corporation Class A on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immuneering Corporation Class A Shares that will get you 0.2970 shares as per Immuneering Corporation Class A share price of $5.05 per share as on June 30, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Immuneering Corporation Class A Stock (IMRX) from India?

    Indian investors can start investing in Immuneering Corporation Class A (IMRX) shares with as little as ₹94.54 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹945.40 in Immuneering Corporation Class A stock (as per the Rupee-Dollar exchange rate as on ). Based on Immuneering Corporation Class A share’s latest price of $5.05 as on June 30, 2026 at 1:29 am IST, you will get 1.9802 shares of Immuneering Corporation Class A. Learn more about fractional shares .